MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data.

Cancers (Basel) · 2023 · PMC9913385 · PMID 36765665

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, Busaidy’s trial which looked at the same question in RAIR-PTC showed a trend in efficacy for the dual therapy, but it was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.